References
- Abrego G, Alvarado HL, Egea MA, et al. (2014). Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen. J Pharm Sci 103:3153–64
- Ali HS, York P, Ali AM, Blagden N. (2011). Hydrocortisone nano-suspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release 149:175–81
- Amrite AC, Edelhauser HF, Singh SR, Kompella UB. (2008). Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis 14:150–60
- Cholkar K, Gilger BC, Mitra AK. (2015a). Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol 4:1
- Cholkar K, Gunda S, Earla R, et al. (2015b). Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech 16:610–22
- Civiale C, Licciardi M, Cavallaro G, et al. (2009). Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int J Pharm 378:177–86
- Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. (2010). Effect of a liposomal spray on the pre-ocular tear film. Cont Lens Anterior Eye 33:83–7
- Fathalla ZM, Khaled KA, Hussein AK, et al. (2015). Formulation and corneal permeation of ketorolac tromethamine-loaded chitosan nanoparticles. Drug Dev Ind Pharm 25:1–11
- Gupta H, Aqil M, Khar RK, et al. (2010). Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 6:324–33
- Gupta H, Aqil M, Khar RK, et al. (2011). Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target 19:409–17
- Huu VA, Luo J, Zhu J, et al. (2015). Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. J Control Release 200:71–7
- Ideta R, Yanagi Y, Tamaki Y, et al. (2004). Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats. FEBS Lett 557:21–5
- Kaiser JM, Imai H, Haakenson JK, et al. (2013). Nanoliposomal minocycline for ocular drug delivery. Nanomedicine 9:130–40
- Kannan S, Dai H, Navath RS, et al. (2012). Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 4:130ra46
- Kassem MA, Abdel Rahman AA, Ghorab MM, et al. (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340:126–33
- Kaur IP, Garg A, Singla AK, Aggarwal D. (2004). Vesicular systems in ocular drug delivery: an overview. Int J Pharm 269:1–14
- Khan MS, Vishakante GD, Bathool A. (2013). Development and characterization of pilocarpine loaded Eudragit nanosuspensions for ocular drug delivery. Biomed Nanotechnol 9:124–31
- Kim H, Robinson SB, Csaky KG. (2009). Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res 26:329–37
- Koo H, Moon H, Han H, et al. (2012). The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 33:3485–93
- Lee KC, Choo HS. (2014). Preparation of poly (BMA-co-MMA) particles by soap-free emulsion polymerization and its optical properties as photonic crystals. Nanosci Nanotechnol 14:8279–87
- Lee SS, Hughes P, Ross AD, Robinson MR. (2010). Biodegradable implants for sustained drug release in the eye. Pharm Res 27:2043–53
- Lee SY, Tong L. (2012). Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci 89:1654–61
- Mudgil M, Pawar PK. (2013). Preparation and in vitro/ex vivo evaluation of moxifloxacin-loaded PLGA nanosuspensions for ophthalmic application. Sci Pharm 81:591–606
- Nicolosi D, Cupri S, Genovese C, et al. (2015). Nanotechnology approaches for antibacterial drug delivery: preparation and microbiological evaluation of fusogenic liposomes carrying fusidic acid. Antimicrob Agents 45:622–6
- Park EJ, Lee GH, Yoon C, et al. (2015a). Biodistribution and toxicity of spherical aluminum oxide nanoparticles. J Appl Toxicol. [Epub ahead of print]. doi: 10.1002/jat.3233
- Park EJ, Oh SY, Kim Y, et al. (2015b). Distribution and immunotoxicity by intravenous injection of iron nanoparticles in a murine model. Appl Toxicol. [Epub ahead of print]. doi: 10.1002/jat.3232
- Patel S, Garapati C, Chowdhury P, et al. (2015). Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application. Ocul Pharmacol Ther 31:215–27
- Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. Pharm Pharmacol 56:827–40
- Pescina S, Sonvico F, Santi P, Nicoli S. (2015). Therapeutics and carriers: the dual role of proteins in nanoparticles for ocular delivery. Curr Top Med Chem 15:369–85
- Prow TW, Bhutto I, Kim SY, et al. (2008). Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 4:340–9
- Raju HB, Hu Y, Vedula A, et al. (2011). Evaluation of magnetic micro and nanoparticle toxicity to ocular tissues. PLoS One 6:e17452. doi: 10.1371/journal.pone.0017452
- Shaunak S, Thomas S, Gianasi E, et al. (2004). Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 22:977–84
- Suresh PK, Sah AK. (2014). Patent perspectives for corticosteroids based ophthalmic therapeutics. Recent Pat Drug Deliv Formul 8:206–23
- Vandamme TF, Brobeck L. (2005). Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 102:23–38
- Varshochian R, Riazi-Esfahani M, Jeddi-Tehrani M, et al. (2015). Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J Biomed Mater Res A 103:3148–56
- Vasconcelos A, Vega E, Pérez Y, et al. (2015). Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery. Int J Nanomedicine 10:609–31
- Wong TY, Ohno-Matsui K, Leveziel N, Holz FG. (2015). Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol 99:289–96
- Zhang L, Li Y, Zhang C, et al. (2009). Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. Int J Nanomedicine 4:175–83
- Zhang R, He R, Qian J, et al. (2010). Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 51:3575–82